Beckley Psytech raises £3m initially to investigate therapeutic use of 5-MeO-DMT

This news update comments "Beckley Psytech will use Series A funding to advance its lead programme exploring the use of synthetic 5-MeO-DMT, a unique psychedelic agent with a short duration of action, in the treatment of neuropsychiatric diseases." The report also comments "Beckley Psytech, the psychedelic medicine company, has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases ... The company is borne out of a strategic partnership with the Beckley Foundation, a renowned non-profit NGO with a 20 year track record of advancing scientific research into psychedelic medicine."